Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine
tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder
and which of these bothersome symptoms are improved with treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.